Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy

Jill Bates, Jill S Bates, Larry W. Buie, C Brock Woodis, C. B. Woodis
Pharmacotherapy · 2011 · vol. 31(11) , pp. 1092–1110 · doi:10.1592/phco.31.11.1092 · PMID:22026397 · W2037044584
Review OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This paper reviews management strategies for menorrhagia in women with hematologic malignancy and chemotherapy-induced thrombocytopenia, discussing preventive and therapeutic options including hormonal therapies and tranexamic acid.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Abnormal uterine bleeding in women with a blood dyscrasia, such as leukemia, or who experience thrombocytopenia secondary to myelosuppressive chemotherapy is a clinical condition associated with significant morbidity. Consequently, effective management is necessary to prevent adverse outcomes. Prevention of menorrhagia, defined as heavy regular menstrual cycles with more than 80 ml of blood loss/cycle or a cycle duration longer than 7 days, in this patient population is the goal of therapy. Gonadotropin-releasing hormone analogs (e.g., leuprolide) are promising therapies that have been shown to decrease vaginal bleeding during periods of thrombocytopenia and to have minimal adverse effects other than those associated with gonadal inhibition. In patients who experience menorrhagia despite preventive therapies, or in patients who have thrombocytopenia and menorrhagia at diagnosis, treatment is indicated. For these women, treatment options may include platelet transfusions, antifibrinolytic therapy (e.g., tranexamic acid), continuous high-dose oral contraceptives, cyclic progestins, or other therapies for more refractory patients such as danazol, desmopressin, and recombinant factor VIIa. Hormonal therapies are often the mainstay of therapy in women with menorrhagia secondary to thrombocytopenia, but data for these agents are sparse. The most robust data for the treatment of menorrhagia are for tranexamic acid. Most women receiving tranexamic acid in randomized trials experienced meaningful reductions in menstrual bleeding, and this translated into improved quality of life; however, these trials were not performed in patients with cancer. Further clinical trials are warranted to evaluate both preventive and therapeutic agents for menorrhagia in premenopausal women with cancer who are receiving myelosuppressive chemotherapy.

My notes (saved in your browser only)

MeSH descriptors

Antineoplastic Agents Menorrhagia Thrombocytopenia Animals Antifibrinolytic Agents Antifibrinolytic Agents Antineoplastic Agents Antineoplastic Agents Female Hematologic Neoplasms Hematologic Neoplasms Humans Menorrhagia Menorrhagia Menorrhagia Quality of Life Thrombocytopenia Thrombocytopenia Tranexamic Acid Tranexamic Acid

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (69)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T05:39:31.692385+00:00
pubmed
last seen: 2026-10-08T21:09:35.770675+00:00
License: CC0 · commercial use OK